Impairment in the hypothalamic–pituitary–gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib
Clicks: 17
ID: 322490
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
17 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #17 of 359 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 359 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Erectile dysfunction (ED) is observed during treatment with the highly selective RET inhibitor selpercatinib. A pathogenic hypothesis is the impairment in the hypothalamic-pituitary-gonadal (HPG) axis. This study aims to analyze variations in the HPG axis in male patients with advanced medullary thyroid carcinoma (MTC) treated with selpercatinib. METHODS: 19 male patients were evaluated for FSH, LH, Total Testosterone (TT), and Sex Hormone Binding Globulin (SHBG). Free Testosterone (FreeT) was estimated. In all patients (total group - T-Group), the HPG axis was evaluated before and after 12 months of selpercatinib initiation. In 7/19 (36.8%) cases (extended group - Ex-Group), data collection was extended beyond 24 months from the start of treatment. Semen analysis was performed in 6 (31.6%) patients. RESULTS: 18/19 (94.7%) patients experienced ED: 2 (11.1%) had ED before, while 16 (88.9%) developed ED after starting selpercatinib. The median time to ED onset was 1 month. During the first year of treatment, a significant increase in FSH (p = 0.03) (+61.9%) was observed in the T-Group. In the Ex-Group, a significant increase in FSH (+60.6%), LH (+20.5%) (p < 0.01), and SHBG (+27.7%) (p = 0.04), and a decrease in TT (-20%) (p = 0.01) and FreeT (-12.5%) (p < 0.01) were observed. Five patients had azoospermia, and one severe oligospermia. CONCLUSIONS: ED shows high prevalence and early onset in males with MTC treated with selpercatinib. Impairment in the HPG axis and semen analysis can reflect damage to Sertoli and Leydig cells, leading to hypogonadism. Therefore, HPG axis evaluation and fertility counseling could be advisable mainly in childbearing males before starting selpercatinib.
| Reference Key |
openalex_W7170198282
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Antonio Matrone, Carla Gambale, Alessandro Prete, Cristina Romei, Roberta Casalini, Piaggi P, Chiara Nencetti, Maria Rita Sessa, Domenico Canale, Rossella Elisei |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag296
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.